

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-7 (Canceled)

8 (Previously amended). A mixed sequence oligonucleotide or oligonucleotide analog including more than one 2'-modified 2'-deoxyfuranosyl moiety wherein said modification comprises substitution by halo, azido, amino, alkoxy, thioalkoxy, alkylamino, or alkyl, and wherein one of said 2'-modified 2'-deoxyfuranosyl moieties is different from another of said 2'-modified 2'-deoxyfuranosyl moieties.

9 (Previously amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy, alkylamino or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by alkyloxy.

10 (Previously amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by methoxy.

11 (Previously amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein alkyl comprises a straight or branched chain alkyl.

12 (Previously amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 11, wherein alkyl includes unsaturation within the alkyl carbon chain.

13 (Previously added). The mixed sequence oligonucleotide of claim 8 wherein said oligonucleotide is a nuclease resistant oligonucleotide.